Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

MET and AKT Genetic Influence on Facial Emotion Perception

  • Ming-Teng Lin ,

    Contributed equally to this work with: Ming-Teng Lin, Kuo-Hao Huang

    Affiliations Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, Department of Psychiatry, Zhudong Veterans Hospital, Hsinchu, Taiwan

  • Kuo-Hao Huang ,

    Contributed equally to this work with: Ming-Teng Lin, Kuo-Hao Huang

    Affiliations Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan

  • Chieh-Liang Huang,

    Affiliation Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan

  • Yu-Jhen Huang,

    Affiliations Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan

  • Guochuan E. Tsai,

    Affiliation Department of Psychiatry, Harbor-UCLA Medical Center, Los Angeles Biomedical Research Institute, Torrance, California, United States of America

  • Hsien-Yuan Lane

    Affiliations Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan

MET and AKT Genetic Influence on Facial Emotion Perception

  • Ming-Teng Lin, 
  • Kuo-Hao Huang, 
  • Chieh-Liang Huang, 
  • Yu-Jhen Huang, 
  • Guochuan E. Tsai, 
  • Hsien-Yuan Lane



Facial emotion perception is a major social skill, but its molecular signal pathway remains unclear. The MET/AKT cascade affects neurodevelopment in general populations and face recognition in patients with autism. This study explores the possible role of MET/AKT cascade in facial emotion perception.


One hundred and eighty two unrelated healthy volunteers (82 men and 100 women) were recruited. Four single nucleotide polymorphisms (SNP) of MET (rs2237717, rs41735, rs42336, and rs1858830) and AKT rs1130233 were genotyped and tested for their effects on facial emotion perception. Facial emotion perception was assessed by the face task of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). Thorough neurocognitive functions were also assessed.


Regarding MET rs2237717, individuals with the CT genotype performed better in facial emotion perception than those with TT (p = 0.016 by ANOVA, 0.018 by general linear regression model [GLM] to control for age, gender, and education duration), and showed no difference with those with CC. Carriers with the most common MET CGA haplotype (frequency = 50.5%) performed better than non-carriers of CGA in facial emotion perception (p = 0.018, df = 1, F = 5.69, p = 0.009 by GLM). In MET rs2237717/AKT rs1130233 interaction, the C carrier/G carrier group showed better facial emotion perception than those with the TT/AA genotype (p = 0.035 by ANOVA, 0.015 by GLM), even when neurocognitive functions were controlled (p = 0.046 by GLM).


To our knowledge, this is the first study to suggest that genetic factors can affect performance of facial emotion perception. The findings indicate that MET variances and MET/AKT interaction may affect facial emotion perception, implicating that the MET/AKT cascade plays a significant role in facial emotion perception. Further replication studies are needed.


Facial emotion perception is a key element of social function [1], [2], [3]. Patients with schizophrenia have deficits in not only facial emotion expression [4], [5] but also facial emotion perception [6]. Better facial emotion perception is related to better work functioning and independent living in patients with schizophrenia [7]. Unaffected siblings of schizophrenia patients are also impaired in emotion perception [8], [9], [10], implying that deficits in facial emotion perception may transmit in families and serve as a heritable endophenotype of schizophrenia. Facial emotion processing is mainly executed in amygdala, right fusiform gyri, and hippocampus in both schizophrenia patients and healthy individuals [11], [12]. Compared to healthy controls, schizophrenic patients have a hypoactivation of amygdala and hippocampus when processing facial emotions [11], [12]. Relative to healthy subjects without family history of psychosis, healthy offspring of schizophrenia patients also have reduced amygdala activity in response to positive emotional faces [13].

Several studies, focusing on monoamine pathways, suggest that genetic variances can determine activities of relevant brain regions when people perceive facial emotion. Non-depressed adults with short allele of deletion polymorphism in the serotonin transporter-linked polymorphic region (5-HTTLPR) have impaired emotion processing and difficulty disengaging attention from facial stimuli [14]. Healthy subjects carrying G allele of serotonin 1A (5HT1A) C(-1019)G polymorphism have decreased amygdala activity when perceiving fear face [15]. Normal individuals with C/C genotype of 5HT3A C178T polymorphism have greater and faster amygdala activity than C/T heterozygotes when performing facial recognition tasks [16]. Bipolar patients' family members who have Val158 allele of catechol-O-methyltransferase (COMT) valine-to-methionine (Val158Met) polymorphism have greater amygdala activity upon receiving sad facial stimuli [17]. COMT Val158Met polymorphism also affects early phase of facial stimuli processing in children [18].

However, whether genetic factors can affect performance of facial emotion perception remains uncertain. In addition, the signal cascades of facial emotion perception deserve further studies because accumulating evidence suggests that regardless of the underlying genetic complexity, the pathophysiology and endophenotypes of schizophrenia may be determined by a small number of common signaling pathways [19], [20].

MET, located at chromosome 7q31, is expressed in amygdala, hippocampus, and cerebral cortex [21], [22], [23]. With 21 exons, MET is vital for cerebral and cerebellar development [24], [25], [26], [27] and interneuron migration, which is implicated in pathophysiology of neurodevelopment disorders such as autism and schizophrenia [27], [28], [29]. MET is associated with autism [29], [30], [31], [32] and face recognition in autistic patients [33], [34], [35]. Schizophrenia shares common genetic factors and clinical features with autism [36], [37]. Furthermore, Burdick et al found that most common GCAATACA haplotype (47%) from rs38857- rs10215153- rs2237717 - rs2283053- rs41735 - rs41741- rs42336 - rs41750 is less-represented in schizophrenia patients and related with better cognitive performances in the healthy group [37]. Among the 8 SNPs, rs2237717, rs41735, and rs42336 were significantly associated with schizophrenia in two independent case-control comparisons [37]. Moreover, MET promoter SNP rs1858830 has been shown to alter gene transcription [29] and be correlated with levels of MET protein [38]. In the current study, we focused on these 4 SNPs.

MET activates phosphorylation of AKT, and this cascade is essential for anti-apoptotic signaling [39] and neuroprotection [40]. The AKT gene is also associated with schizophrenia [41], [42], [43]. Haloperidol, a dopamine receptor antagonist, can increase phosphorylation of AKT proteins in brains of mice, implying that AKT may be involved in the dopamine neurotransmission pathway [41]. One SNP (rs1130233) of AKT can affect amount of AKT protein in lymphocytes and postmortem frontal cortex and hippocampus regions [41]. Subjects with the A allele of AKT rs1130233 have impaired executive function, processing speed, trail making, verbal and category fluency and prefrontal cortical structure [44]. AKT is also involved in fear memory learning via the amygdala, a crucial area for emotion perception [45]. However, the role of AKT in emotion perception requires elucidation.

This study aimed to testify the genetic effects of the MET and AKT cascade on facial emotion perception in healthy individuals.


This study was approved by the Institutional Review Board of China Medical University Hospital (CMUH), the authors' institutional review board, and performed in accordance with the Declaration of Helsinki. After complete description, all subjects gave written informed consent.


The participants were 182 unrelated Han Chinese healthy individuals (82 men and 100 women) with a mean age of 31.52 (SD = 9.58, range 20–65) years and a mean education level of 14.91 (SD = 2.21, range 6–23 years). All were Han Chinese living in Taiwan. They were free of any axis I or II psychiatric disorders, as determined by a research psychiatrist using the Structured Clinical Interview for DSM-IV [46]. They were also in good physical health, as determined by physical examination, electrocardiogram and laboratory tests including liver, renal and thyroid function tests and urinalysis. After complete description, all subjects gave written informed consent.

Measurement of facial emotion perception

This study utilized the face task of the emotion perception branch of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) [47]. MSCEIT is divided into four branches: perceiving emotion (consisting of two tasks: face and picture tasks), facilitating emotion, understanding emotion, and managing emotion [48]. The face task of emotion perception could reflect the ability of being aware of emotional cues before identifying what they mean accurately. In the face task (with four item parcels, each with five responses), participants viewed a series of faces and responded to each one on a five-point scale, indicating the degree to which a specific emotion was present in a face. Patients rated all of the five emotions (happiness, sadness, fear, surprise, and excitement) sequentially [47]. The results were scaled to a standard score based on the weight from the representative adult population (regarding age, gender, and ethnicity) in an extremely large sample of people (5,000) [47]. The reliability and validity of MSCEIT V2.0 have been demonstrated to be favorable in various races [47], [49] including Han-Chinese [50].

Measurement of cognitive functions

An experienced research psychologist comprehensively assessed cognitive functions to control for their possible effects when we explored genetic effects on facial emotion perception. Among all 182 subjects, 149 also received thorough cognition assessments with a battery of tests, which were the same as or the analogues of tests from Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) [51], [52]. This battery included 7 domains: (1) speed of processing, consisting of 3 tests: Category Fluency, Trail Marking A, and WAIS-III Digit Symbol-Coding [53], [54]; (2) sustained attention by Continuous Performance Test [55]; (3) working memory, verbal (backward digit span) and nonverbal (WMS-III, Spatial Span) [56]; (4) verbal learning and memory (WMS-III, word listing) [56]; (5) visual learning and memory (WMS-III, visual reproduction) [56]; (6) reasoning and problem solving (WISC-III, Maze) [57], and (7) social cognition, measured by the managing emotions branch of MSCEIT [47]. Mean score of each domain was standardized to a T score with a mean of 50 and a standard deviation of 10. For the domain with more than one test, an overall composite score was calculated by standardizing the sum of T scores [58].

DNA extraction

Peripheral bloods from schizophrenia subjects were collected in EDTA-tubes. The DNA was isolated by employing the salting-out method [59], and stored in a TE-buffer at 2–8°C. The sample concentrations were measured with a UV/Vis spectrophotometer (Nanodrop ND-1000, Thermo Scientific).


Four SNPs (rs2237717, rs41735, rs42336, and rs1858830) of the MET gene and rs1130233 of the AKT gene were selected due to associations with schizophrenia [37], [41], [44] and with performances of neurocognition tests in previous studies [37], [44]. To determine genotyping from venous blood samples, the 5 SNPs expect rs1858830 were amplified via PCR amplification before being subjected to analysis by high resolution melting method (HRM) in ABI 7500 Fast Real-time PCR system (Life technologies).

The sequences of the primers for the MET gene were: for rs2237717, sense primer 5′- CCA CGT ACT TCA TCA ATG -3′ and antisense primer 5′- CTT CCT GGC AAT AAA GAG -3′; for rs41735, sense primer 5′- GCT ATT GGA AAA GAA AAG GAT AGA AAC -3′ and antisense primer 5′- CCA TCT GTA GTT GGT AGA ATA TCT CT -3′; for rs42336, sense primer 5′- AGA GAA CTA GAT TAC GTC AGC CAA AGA -3′ and antisense primer 5′- TCT GCC CTG GGG TCA CAT -3′. For rs1130233 of AKT, sense primer 5′-GCT GTT CTT CCA CCT GTC -3′ and antisense primer 5′-AGG GCT GAC ACA ATC TCA -3′. Neither a TaqMan Assay-by-Design nor a high resolution melting method (HRM) in ABI 7500 Fast Real-time PCR system (Life technologies) was able to reliably provide rs1858830 genotype from genomic DNA, probably because of ≈85% GC in the region. Therefore the genotype at rs1858830 was determined by direct resequencing.

PCR was performed in a 20-µl volume containing the following: 1× PCR reaction buffer, 1 U FastStart Taq DNA Polymerase (Roche), 0.3 µM of each primer, 1.5 µM SYTO® 9 green fluorescent nucleic acid stain (Life technologies), and 20 ng DNA template, with a 2 mM final MgCl2 concentration. The cycling conditions were as follows: denaturation at 95°C for 4 min, followed by 35 cycles of 95°C for 30 s, 58–64°C for 30 s (for MET gene: rs2237717 and rs41735 at 58°C; rs42336 at 64°C, and for AKT gene: rs1130233 at 63°C), and 72°C for 45 s, followed by one HRM cycle of 95°C for 10 s, 60°C for 1 min, and continuous acquisition to 95°C for 15 s (ramp rate 1%), and subsequently down to 60°C for 15 s. The HRM data were analyzed using the high resolution melting (HRM) software, version 2.0.1. All melting curves deviating from the wild-type curve and appearing as a different color in discrete plots contain a variant potentially. In addition, 24 randomly selected samples including three genotypes of one SNP which identified by HRM were sent to direct sequencing by Mission Biotech CO., LTD, Taiwan.

Data analysis

All the statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS), version 17.0 for Windows. Deviation of the genotype counts from the Hardy–Weinberg equilibrium was tested by employing a Chi-Square goodness-of-fit test. Chi-Square test was used for gender comparisons between genetic groups. Age, years of education, facial emotion perception and composite cognition between genetic groups was test by ANOVA. Bonferroni correction was used in post-hoc analysis. Linkage disequilibrium structure was examined using Haploview 4.2 [60] with solid spine D′>0.80 (Figure S1). MET haplotype and diplotype were reconstructed via SAS/GENETICS by implementing the PROC HAPLOTYPE procedure (SAS® 9.1 software). Because MET could induce phosphorylation of AKT [39], interactions between MET and AKT may be present in facial emotion perception. Therefore, this study divided subjects into four groups according to the genotype status and function assessment in the previous studies [29], [32], [37], [41], [44] to explore potential interactions between MET (rs2237717) and AKT (rs1130233) genotypes. The four groups of MET/AKT were TT/AA, TT/G carrier, C carrier/AA, and C carrier/G carrier.

General linear models (GLM) were utilized to test the main effects of MET, AKT, and MET/AKT combination on facial emotion perception, and control variables were age, gender, and years of education as covariates or fixed factors as appropriate. This study utilized partial η2 (eta squared) by SPSS [61] to estimate the effect size in GLM. We also calculated the effect sizes (Cohen's d) [62] of the MET, AKT, and MET/AKT status to testify whether the combined gene effect was additive or synergistic. Finally, this study utilized G* power 3 [63] to estimate the power and defined the results as statistically significant if the p-values were below 0.05 (two-sided).


All four SNPs of MET and AKT rs1130233 did not deviate from the Hardy-Weinberg equilibrium. Genotype and allele frequencies of the five SNPs were similar to those of other studies [37], [64], [65] (Table 1 and Table S1). There were high linkage among MET rs2237717, rs41735, and rs42336 (D′>0.9); therefore, we constructed haplotype block among the 3 SNPs (Figure S1). In this haplotype block, the most common two haplotypes from MET rs2237717, rs41735, and rs42336 were CGA and TAG (frequency = 0.505, 0.425, respectively). There were only 2 subjects with CAG haplotype, and their mean [SD] facial emotion perception (88.9[11.0]) was similar to that (84.3[20.5]) of the TAG group; we therefore combined CAG with TAG as the non-CGA group.

Table 1. Demographics and facial emotion perception of individuals with different MET SNPs, MET CGA haplotypes, AKT SNP, and MET/AKT interaction variants.

Demographic characteristics and emotion perception performance by MET genotype, AKT genotype, MET haplotypes, and MET-AKT are shown in Table 1. Age, gender, and years of education were similar among groups by MET genotypes, AKT genotypes, or CGA haplotype.

Performances of facial emotion perception were different among 3 genotype groups of MET rs2237717 (p = 0.048, F = 3.09, df = 2). Bonferroni post hoc analysis revealed this difference was driven from difference between CT and TT (p = 0.049; uncorrected p = 0.016, power = 0.699). There was a dominant effect of the C allele of MET rs2237717, since there was no difference between CT and CC in terms of performance. No differences of facial emotion perception were observed in the other three MET SNPs and AKT rs113023 (Table 1). MET CGA haplotype had significant effect on facial emption perception (p = 0.018, df = 1, F = 5.69). Subjects with MET CGA haplotype also performed better than non-CGA individuals in facial emotion perception by GLM analysis (p = 0.009) (Table 2).

Table 2. General linear regression analyses of effects of the MET SNPs, MET CGA haplotypes, AKT SNP, and MET/AKT interaction on facial emption perception.*

Considering the combined effect of MET and AKT variants, we analyzed MET rs2237717 and AKT rs1130233 simultaneously. Facial emotion perceptions were different among four combinations of MET/AKT variants (p = 0.031, df = 3, F = 3.03). The Bonferroni post-hoc analysis showed that the difference was driven from the comparison between the individuals who were simultaneously C carriers and G carriers and those with TT/AA (p = 0.035, uncorrected p = 0.006). In addition, there was nominal difference between TT/AA and C carrier/AA (p = 0.049); however it did not survive after Bonferroni correction (p = 0.296).

As shown on Table 2, after control for age, gender, and education duration, CC and CT genotypes of MET rs2237717increased facial emotion perception by 9.987, 8.766, respectively (p = 0.015, 0.018, respectively) when compared with TT genotype. As for MET rs42336, AA homozygotes had better performance than those with GG genotype by 8.686 (p = 0.041). Subjects with MET CGA haplotype had better emotion perception by 8.748 than those without this haplotype (p = 0.009). However, MET rs41735, rs1858830 and AKT rs1130233 did not affect facial emotion perception (Table 2). In addition, each year increase in education duration increased performance of facial emotion perception by 1.86–2.06 (data not shown). Men had better facial emotion perception than women by 4.87 (p = 0.048) in general linear regression analysis for MET rs2237717. Other confounding variables did not significantly influence facial emotion perception.

To explore the combined effect of MET and AKT variants, we chose MET rs2237717 and AKT rs1130233, because MET rs2237717 had the most significant influence on facial emotion perception in the current study and AKT rs1130233 had been shown to be functional in the previous studies [41], [44]. In the general linear analysis controlling age, gender, and education, the overall effect of MET/AKT on facial emotion perception was significant (p = 0.041). When the individuals who were C carrier and G carrier simultaneously were used as the reference group, their facial emotion perception was better than that of those with TT/AA (p = 0.015, Table 2). To inspect the influence of the combined effect of both genes on facial emotion perception, effect sizes of MET rs2237717, AKT rs1130233, and MET/AKT combination were compared (Figure 1).This result showed a possible additive effect of the two genes on facial emotion perception.

Figure 1. MET rs2237717 and AKT rs1130233 combined effect on facial emotion perception.

Compared with TT/AA of MET/AKT, C carrier/G carrier had a Cohen's d (0.822), which was similar with the sum (0.704) of Cohen's d of MET rs2237717 (d = 0.439) and AKT rs1130233 (d = 0.265), indicating an additive effects of the two SNPs on facial emotion perception.

To evaluate the possible effect of cognitive functions on facial emotion perception, we further explored the 149 patients who also received thorough cognition assessments. Demographic data and facial emotion perception in the 149 patients Table S2) were similar to those in the all 182 subjects. MET rs2237717, MET CGA haplotype and MET/AKT combination still had significant effects on facial emotion perception (Table S2). MET and AKT variants had no significant influence on cognitive function (Table S2). Effects of MET/AKT variants were also analyzed by general linear regression analysis in the 149 subjects. After control for age, gender, education duration, and neurocognition, subjects with CC and CT genotypes of MET rs2237717 had better facial emotion perception when compared with TT genotype(p = 0.035, 0.037, respectively). Subjects with MET CGA haplotype had better emotion perception than those without this haplotype (p = 0.020) (details not shown). The participants who were C carrier/G carrier of MET/AKT were superior to those with TT/AA in facial emotion perception (p = 0.046, Table 3). Neurocognition did not affect facial emotion perception (Table 3).

Table 3. General linear regression analysis of the MET/AKT variants for facial emption perception in 149 subjects who also received comprehensive cognitive tests.


Sensory perception, especially facial emotion recognition, is crucial for social skill in humans [66]. To our knowledge, this study is the first one which demonstrates that genes can affect performance of facial emotion perception. The findings suggest that MET's rs2237717 genotype and CGA haplotype from rs2237717, rs41735, and rs42336 of can alter facial emotion perception, and that AKT gene may enhance the influence of MET on facial emotion perception. The C allele of rs1858830 in the MET promoter region has been reported to be associated with autism [29], [30]; however, the current study failed to find its influence on facial emotion perception. One of the possible explanations is the different ethnicities. Previous Japanese and Chinese studies [65], [67] also did not find an association between MET rs1858830 and autism, but did find an association between MET rs38841 and 38845 and autism [65], [67]. In genetic studies, different associated variants may be reported in the same region in heterogeneous disorders such as autism and schizophrenia [68].

Burdick et al [37] found that the haplotype GCAATACA from rs38857- rs10215153- rs2237717- rs2283053- rs41735- rs41741- rs42336- rs41750 of MET was associated with better neurocognitive ability in healthy subjects. However, CGA haplotype in the current study did not affect cognitive function (Table S1). The possible reasons include differences in cognitive tests, ethnicity, and haplotypes between studies.

The A allele of AKT rs1130233 was reported to be associated with reduced cognitive functions [44]; the current study showed the same trend for facial emotion perception, albeit statistically insignificant (Table S1) (perhaps due to the modest sample size). AKT is also involved with emotional memory learning in the amygdala, which is a critical area in emotion perception [45]. In spite of insignificant effect of AKT variants on facial emotion perception, the present study revealed that AKT had additive effect with MET on facial emotion perception: the individuals who were both C carriers/G carriers of MET/AKT had better emotion perception than those with TT/AA. Therefore, this finding suggests that the AKT gene may modulate the MET effect on facial emotion perception. Such gene-gene interactions are pretty common in CNS signal pathways. One recent example is the interaction of Neuregulin-1 (NRG-1) and its receptor, ERBB4 [69], [70]. Schizophrenia patients who carried 3 NRG1/ERBB4/AKT risk genotypes were disproportionately worse in dorsolateral prefrontal function in the image study [69].

Consistent with a previous study [71], the current study showed that higher education level was associated with better facial emotion perception. However, MET genotype, haplotype and MET/AKT combination still exerted significant effects on facial emotion perception after control for education level.

The present study had some limitations, such as utilizing the face task of the emotion perception branch of MSCEIT, which only reflects the general ability of facial emotion perception. However, the face task of emotion perception can also be an important component of social cognition [4], [72], [73]. Second, this study focused on healthy Han-Chinese subjects. Whether the finding can be extrapolated to mentally ill patients or other races remain unknown. Third, the sample size in this study was only modest; however, the power of effects of MET and MET/AKT was medium to large. Future studies with larger samples in other ethnicities are warranted.

In summary, the results suggest that the MET/AKT cascade may play a role in facial emotion perception. Further studies in other races or in patients with mental disorders such as schizophrenia are needed.

Supporting Information

Figure S1.

Linkage disequilibrium (D′) for the MET SNPs was computed using Haploview 4.2.


Table S1.

Allele frequencies of MET SNPs and AKT SNP.


Table S2.

Demographics, facial emotion perception, composite cognition*, and MET SNPs and haplotypes, AKT SNP, and MET/AKT variants in the 149 patients who also received thorough cognitive assessments.


Author Contributions

Conceived and designed the experiments: HYL. Performed the experiments: MTL KHH. Analyzed the data: MTL KHH. Contributed reagents/materials/analysis tools: MTL KHH. Wrote the paper: MTL KHH HYL. Conducted the study and wrote the protocol: CLH YJH GET.


  1. 1. Zaja RH, Rojahn J (2008) Facial emotion recognition in intellectual disabilities. Curr Opin Psychiatry 21: 441–444.
  2. 2. Ihnen GH, Penn DL, Corrigan PW, Martin J (1998) Social perception and social skill in schizophrenia. Psychiatry Res 80: 275–286.
  3. 3. Pinkham AE, Penn DL, Perkins DO, Graham KA, Siegel M (2007) Emotion perception and social skill over the course of psychosis: a comparison of individuals “at-risk” for psychosis and individuals with early and chronic schizophrenia spectrum illness. Cogn Neuropsychiatry 12: 198–212.
  4. 4. Kee KS, Horan WP, Salovey P, Kern RS, Sergi MJ, et al. (2009) Emotional intelligence in schizophrenia. Schizophr Res 107: 61–68.
  5. 5. Mandal MK, Pandey R, Prasad AB (1998) Facial expressions of emotions and schizophrenia: a review. Schizophr Bull 24: 399–412.
  6. 6. Chan RC, Li H, Cheung EF, Gong QY (2010) Impaired facial emotion perception in schizophrenia: a meta-analysis. Psychiatry Res 178: 381–390.
  7. 7. Kee KS, Green MF, Mintz J, Brekke JS (2003) Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull 29: 487–497.
  8. 8. Kee KS, Horan WP, Mintz J, Green MF (2004) Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res 67: 87–94.
  9. 9. Leppanen JM, Niehaus DJ, Koen L, Du Toit E, Schoeman R, et al. (2008) Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia patients: evidence for a neurocognitive endophenotype. Schizophr Res 99: 270–273.
  10. 10. Li H, Chan RC, Zhao Q, Hong X, Gong QY (2010) Facial emotion perception in Chinese patients with schizophrenia and non-psychotic first-degree relatives. Prog Neuropsychopharmacol Biol Psychiatry 34: 393–400.
  11. 11. Li H, Chan RC, McAlonan GM, Gong QY (2010) Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr Bull 36: 1029–1039.
  12. 12. Rametti G, Junque C, Vendrell P, Catalan R, Penades R, et al. (2009) Hippocampal underactivation in an fMRI study of word and face memory recognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259: 203–211.
  13. 13. Barbour T, Murphy E, Pruitt P, Eickhoff SB, Keshavan MS, et al. (2010) Reduced intra-amygdala activity to positively valenced faces in adolescent schizophrenia offspring. Schizophr Res 123: 126–136.
  14. 14. Beevers CG, Wells TT, Ellis AJ, McGeary JE (2009) Association of the serotonin transporter gene promoter region (5-HTTLPR) polymorphism with biased attention for emotional stimuli. J Abnorm Psychol 118: 670–681.
  15. 15. Fakra E, Hyde LW, Gorka A, Fisher PM, Munoz KE, et al. (2009) Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. Arch Gen Psychiatry 66: 33–40.
  16. 16. Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, et al. (2005) A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 25: 6460–6466.
  17. 17. Lelli-Chiesa G, Kempton MJ, Jogia J, Tatarelli R, Girardi P, et al. (2011) The impact of the Val158Met catechol-O-methyltransferase genotype on neural correlates of sad facial affect processing in patients with bipolar disorder and their relatives. Psychol Med 41: 779–788.
  18. 18. Battaglia M, Zanoni A, Giorda R, Pozzoli U, Citterio A, et al. (2007) Effect of the catechol-O-methyltransferase val(158)met genotype on children's early phases of facial stimuli processing. Genes Brain Behav 6: 364–374.
  19. 19. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, et al. (2010) Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31: 381–390.
  20. 20. Kvajo M, McKellar H, Gogos JA (2010) Molecules, Signaling, and Schizophrenia. In: Swerdlow NR, editor. Behavioral Neurobiology of Schizophrenia and Its Treatment: Springer Berlin Heidelberg. pp. 629–656.
  21. 21. Honda S, Kagoshima M, Wanaka A, Tohyama M, Matsumoto K, et al. (1995) Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res 32: 197–210.
  22. 22. Sun W, Funakoshi H, Nakamura T (2002) Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex. Brain Res Mol Brain Res 103: 36–48.
  23. 23. Judson MC, Bergman MY, Campbell DB, Eagleson KL, Levitt P (2009) Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain. J Comp Neurol 513: 511–531.
  24. 24. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925.
  25. 25. Ieraci A, Forni PE, Ponzetto C (2002) Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc Natl Acad Sci U S A 99: 15200–15205.
  26. 26. Powell EM, Mars WM, Levitt P (2001) Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron 30: 79–89.
  27. 27. Judson MC, Eagleson KL, Levitt P (2011) A new synaptic player leading to autism risk: Met receptor tyrosine kinase. J Neurodev Disord 3: 282–292.
  28. 28. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S (2010) Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 67: 155–166.
  29. 29. Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, et al. (2006) A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A 103: 16834–16839.
  30. 30. Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P (2008) Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 1: 159–168.
  31. 31. Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mirnics K, et al. (2007) Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol 62: 243–250.
  32. 32. Sousa I, Clark TG, Toma C, Kobayashi K, Choma M, et al. (2009) MET and autism susceptibility: family and case-control studies. Eur J Hum Genet 17: 749–758.
  33. 33. Dawson G, Webb SJ, McPartland J (2005) Understanding the nature of face processing impairment in autism: insights from behavioral and electrophysiological studies. Dev Neuropsychol 27: 403–424.
  34. 34. Sasson NJ (2006) The development of face processing in autism. J Autism Dev Disord 36: 381–394.
  35. 35. Dawson G, Webb SJ, Wijsman E, Schellenberg G, Estes A, et al. (2005) Neurocognitive and electrophysiological evidence of altered face processing in parents of children with autism: implications for a model of abnormal development of social brain circuitry in autism. Dev Psychopathol 17: 679–697.
  36. 36. Rzhetsky A, Wajngurt D, Park N, Zheng T (2007) Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A 104: 11694–11699.
  37. 37. Burdick KE, DeRosse P, Kane JM, Lencz T, Malhotra AK (2010) Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry 167: 436–443.
  38. 38. Heuer L, Braunschweig D, Ashwood P, Van de Water J, Campbell DB (2011) Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. Transl Psychiatry 1: e48.
  39. 39. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, et al. (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 98: 247–252.
  40. 40. Hossain MA, Russell JC, Gomez R, Laterra J (2002) Neuroprotection by scatter factor/hepatocyte growth factor and FGF-1 in cerebellar granule neurons is phosphatidylinositol 3-kinase/akt-dependent and MAPK/CREB-independent. J Neurochem 81: 365–378.
  41. 41. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131–137.
  42. 42. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, et al. (2005) Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 58: 446–450.
  43. 43. Xu MQ, Xing QH, Zheng YL, Li S, Gao JJ, et al. (2007) Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 68: 1358–1367.
  44. 44. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, et al. (2008) Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 118: 2200–2208.
  45. 45. Lin CH, Lee CC, Gean PW (2003) Involvement of a calcineurin cascade in amygdala depotentiation and quenching of fear memory. Mol Pharmacol 63: 44–52.
  46. 46. American Psychiatric Association, Task Force on DSM-IV (2000) Diagnostic and statistical manual of mental disorders : DSM-IV-TR. Washington, DC: American Psychiatric Association. xxxvii, 943 p..
  47. 47. Mayer JD, Salovey P, Caruso DR, Sitarenios G (2003) Measuring emotional intelligence with the MSCEIT V2.0. Emotion 3: 97–105.
  48. 48. Mayer JD, Salovey PS, Caruso DR, editors. (2002) Mayer-Salovey-Caruso emotional intelligence test user's manual (MESCEIT) item booklet. Toronto, Ontario, Canada: MHS Publishers.
  49. 49. Eack SM, Greeno CG, Pogue-Geile MF, Newhill CE, Hogarty GE, et al. (2010) Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test. Schizophr Bull 36: 370–380.
  50. 50. Lo CH, Tsai GE, Liao CH, Wang MY, Chang JP, et al. (2010) Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biol Psychol 83: 79–83.
  51. 51. Marder SR, Fenton W (2004) Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 72: 5–9.
  52. 52. Kern RS, Green MF, Nuechterlein KH, Deng BH (2004) NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res 72: 11–19.
  53. 53. Sanchez-Cubillo I, Perianez JA, Adrover-Roig D, Rodriguez-Sanchez JM, Rios-Lago M, et al. (2009) Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 15: 438–450.
  54. 54. Wechsler D (1997) Wechsler Adult Intelligence Scale (3rd ed). San Antonio, TX.: The psychological corporation.
  55. 55. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, et al. (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 155: 1214–1220.
  56. 56. Wechsler D (1997) Wechsler Memory Scale-Third edication. San Antonio, TX.: The psychological corporation.
  57. 57. Wechsler D (1991) Wechsler Intelligence Scale for Child (3rd ed). San Antonio, TX.: The psychological corporation.
  58. 58. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, et al. (2008) The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 165: 214–220.
  59. 59. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
  60. 60. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
  61. 61. Pierce CA, Block RA, Aguinis H (2004) Cautionary Note on Reporting Eta-Squared Values from Multifactor ANOVA Designs. Educational and Psychological Measurement 64: 916–924.
  62. 62. Cohen J (1988) Statistical power analysis for the behavioral sciences. Hillsdale, N.J.: L. Erlbaum Associates. xxi, 567 p..
  63. 63. Erdfelder E, Faul F, Buchner A (1996) GPOWER: A general power analysis program. Behavior Research Methods 28: 1–11.
  64. 64. Liu YL, Fann CS, Liu CM, Wu JY, Hung SI, et al. (2006) Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population. Psychiatr Genet 16: 39–41.
  65. 65. Zhou X, Xu Y, Wang J, Zhou H, Liu X, et al. (2011) Replication of the association of a MET variant with autism in a Chinese Han population. PLoS One 6: e27428.
  66. 66. Wilhelm O, Herzmann G, Kunina O, Danthiir V, Schacht A, et al. (2010) Individual differences in perceiving and recognizing faces-One element of social cognition. J Pers Soc Psychol 99: 530–548.
  67. 67. Thanseem I, Nakamura K, Miyachi T, Toyota T, Yamada S, et al. (2010) Further evidence for the role of MET in autism susceptibility. Neurosci Res 68: 137–141.
  68. 68. Clarke GM, Carter KW, Palmer LJ, Morris AP, Cardon LR (2007) Fine mapping versus replication in whole-genome association studies. Am J Hum Genet 81: 995–1005.
  69. 69. Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, et al. (2010) Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry 67: 991–1001.
  70. 70. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, et al. (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12: 824–828.
  71. 71. Hofer A, Benecke C, Edlinger M, Huber R, Kemmler G, et al. (2009) Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. Eur Psychiatry 24: 27–32.
  72. 72. Edwards J, Pattison PE, Jackson HJ, Wales RJ (2001) Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 48: 235–253.
  73. 73. Whittaker JF, Deakin JF, Tomenson B (2001) Face processing in schizophrenia: defining the deficit. Psychol Med 31: 499–507.